Bristol Myers Squibb Company
430 E. 29th St
14th Floor
New York
New York
10016
United States
Tel: +1-800-332-2056
Website: http://www.bms.com/
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history.
We work every day to transform patients’ lives through science. Each day, our employees around the world work together for patients – they are at the center of everything we do. They inspire us. They are the reason we come to work each day.
We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.
Possibility Lives at BMS!
2802 articles about Bristol Myers Squibb Company
-
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
-
Building on a previous 2021 collaboration, Bristol Myers Squibb is paying $100 million upfront for the development of five cardiovascular targets utilizing Avidity Biosciences’ antibody oligonucleotide conjugates.
-
The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.
-
After Bristol Myers Squibb picked up Augtyro as part of its $4.1 billion takeover of Turning Point Therapeutics last year, the ROS1-positive non-small cell lung cancer drug reached the regulatory finish line on Wednesday.
-
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
11/15/2023
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
-
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
11/9/2023
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2023 Jefferies London Healthcare Conference in London, England, on Thursday, November 16, 2023.
-
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
11/9/2023
Bristol Myers Squibb announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application for Breyanzi to expand its current indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received a prior Bruton tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor.
-
Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
11/8/2023
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY).
-
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
11/6/2023
Bristol Myers Squibb (NYSE: BMY) today announced that research across the company’s cardiovascular franchise will be presented at the American Heart Association’s (AHA) annual Scientific Sessions, taking place November 11-13, 2023 in Philadelphia, Pennsylvania.
-
After its deal with Tubulis in April 2023, Bristol Myers Squibb is continuing its antibody-drug conjugate buying spree by acquiring an asset from South Korea’s Orum Therapeutics.
-
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
11/2/2023
Bristol Myers Squibb announced the presentation of research across its hematology and cell therapy portfolio and pipeline at the 65th American Society of Hematology Annual Meeting and Exposition, which will take place in San Diego, California from December 9 to 12, 2023.
-
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
11/2/2023
Bristol Myers Squibb announced that the company will participate in the 2023 UBS BioPharma Conference in Miami Beach, Florida, on Wednesday, November 8, 2023.
-
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
10/31/2023
Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $4.5 billion (collectively, the “Notes”).
-
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
10/31/2023
Bristol Myers Squibb (NYSE: BMY) announced that its Board of Directors has unanimously elected Christopher Boerner, Ph.D., to serve as Chair of the Board, effective April 1, 2024.
-
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
10/30/2023
Bristol Myers Squibb announced that the European Medicines Agency has validated its type II variation application for Opdivo in combination with cisplatin-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma, based on results from the Phase 3 CheckMate -901 trial.
-
Merck and Novartis beat expectations this week with solid third-quarter financial results, while BMS, Sanofi and Takeda spooked investors with negative near- and mid-term projections.
-
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
10/26/2023
Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2023, which reflect significant pipeline progress and advances in the company's portfolio renewal strategy.
-
The company on Thursday said it now expects more than $10 billion in new product sales in 2026, despite previously forecasting $10 billion to $13 billion in 2025.
-
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
10/24/2023
Bristol Myers Squibb announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist, for the treatment of progressive pulmonary fibrosis, a devastating, life-threatening illness.
-
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
10/24/2023
LianBio announced that the company has entered into an agreement with Bristol Myers Squibb, whereby BMS has obtained LianBio’s exclusive rights to develop and commercialize mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand, in conjunction with termination of the exclusive license agreement LianBio previously entered into with MyoKardia, Inc., now a wholly owned subsidiary of BMS, in August 2020 to acquire such rights.